📣 VC round data is live. Check it out!

C-Rad Valuation Multiples

Discover revenue and EBITDA valuation multiples for C-Rad and similar public comparables like Fonar, Fractyl Health, SDI Group, Onyx Healthcare and more.

C-Rad Overview

About C-Rad

C-Rad AB is a Sweden-based company engaged in the development and sales of systems with applications in radiation therapy for the treatment of cancer. The systems can be used to position the patient before the treatment and to localize and monitor the tumor by recording information such as patient movements during radiation treatment. Its product portfolio includes the Catalyst and Sentinel systems. Geographically, the company generates a majority of its revenue from Asia Pacific region, and also has its presence in Europe, Middle East and Africa and the rest from Americas.


Founded

2004

HQ

Sweden

Employees

99

Website

c-rad.com

Financials (LTM)

Revenue: $49M
EBITDA: $7M

EV

$107M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

C-Rad Financials

C-Rad reported last 12-month revenue of $49M and EBITDA of $7M.

In the same LTM period, C-Rad generated $35M in gross profit, $7M in EBITDA, and $3M in net income.

Revenue (LTM)


C-Rad P&L

In the most recent fiscal year, C-Rad reported revenue of $50M and EBITDA of $6M.

C-Rad is profitable as of last fiscal year, with gross margin of 68%, EBITDA margin of 13%, and net margin of 2%.

See analyst estimates for C-Rad
LTMLast FY202320242025202620272028
Revenue$49M$50M$46M$50M$47M
Gross Profit$35M$34M$31M$35M$34M
Gross Margin70%68%68%69%72%
EBITDA$7M$6M$6M$10M$3M
EBITDA Margin14%13%13%19%6%
EBIT Margin13%13%12%15%14%
Net Profit$3M$1M$4M$6M$1M
Net Margin6%2%8%12%2%

Financial data powered by Morningstar, Inc.

C-Rad Stock Performance

C-Rad has current market cap of $121M, and enterprise value of $107M.

Market Cap Evolution


C-Rad's stock price is $3.66.

C-Rad share price decreased by 2.1% in the last 30 days, and by 5.5% in the last year.

C-Rad has an EPS (earnings per share) of $0.04.

See more trading valuation data for C-Rad
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$107M$121M-1.3%-2.1%29.7%-5.5%$0.04

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

C-Rad Valuation Multiples

C-Rad trades at 2.2x EV/Revenue multiple, and 15.2x EV/EBITDA.

See NTM and 2027E valuation multiples for C-Rad

EV / Revenue (LTM)


C-Rad Financial Valuation Multiples

As of June 3, 2026, C-Rad has market cap of $121M and EV of $107M.

C-Rad has a P/E ratio of 39.6x.

LTMLast FY202320242025202620272028
EV/Revenue2.2x2.2x2.4x2.1x2.3x
EV/EBITDA15.2x17.3x18.8x11.1x36.9x
EV/EBIT16.3x16.5x20.1x14.2x16.5x
EV/Gross Profit3.1x3.2x3.5x3.1x3.2x
P/E39.6x103.3x31.7x19.9x107.6x
EV/FCF-19.9x60.7x42.7x19.9x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified C-Rad Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

C-Rad Margins & Growth Rates

C-Rad decreased revenue by 1% but EBITDA grew by 32% in the last fiscal year.

In the most recent fiscal year, C-Rad reported gross margin of 68%, EBITDA margin of 13%, and net margin of 2%.

See estimated margins and future growth rates for C-Rad

C-Rad Margins

Last FY202420252026202720282029
Gross Margin68%69%72%72%
EBITDA Margin13%19%6%17%
EBIT Margin13%15%14%16%
Net Margin2%12%2%11%
FCF Margin11%5%11%-

C-Rad Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(1%)10%(6%)3%
Gross Profit Growth4%12%(2%)4%
EBITDA Growth32%69%(70%)183%
EBIT Growth21%41%(14%)21%
Net Profit Growth381%59%(81%)401%
FCF Growth-42%115%-

Data powered by FactSet, Inc. and Morningstar, Inc.

C-Rad Operational KPIs

C-Rad's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.

C-Rad's Rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

C-Rad's Rule of X is 25% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for C-Rad
LTMLast FY202320242025202620272028
Rule of 4018%20%---
Bessemer Rule of X24%25%---
Revenue per Employee-$0.5M---
Opex per Employee-$0.3M---
Opex to Revenue-55%56%54%58%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

C-Rad Competitors

C-Rad competitors include Fonar, Fractyl Health, SDI Group, Onyx Healthcare, JETEMA Co., AVITA Medical, Emvision, Vivani Medical, SANUWAVE Health and Zepp Health.

Most C-Rad public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Fonar1.0x-5.7x-
Fractyl Health--(1.3x)(1.4x)
SDI Group1.7x1.5x9.2x7.7x
Onyx Healthcare2.9x-26.0x-
JETEMA Co.3.7x-24.9x-
AVITA Medical2.3x2.1x(4.1x)(4.8x)
Emvision-26.0x-(16.9x)
Vivani Medical--(4.1x)-

This data is available for Pro users. Sign up to see all C-Rad competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About C-Rad

Who are competitors of C-Rad?C-Rad main competitors include Fonar, Fractyl Health, SDI Group, Onyx Healthcare, JETEMA Co., AVITA Medical, Emvision, Vivani Medical, SANUWAVE Health, Zepp Health.

See public comps similar to C-Rad

Lists including C-Rad

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial